NCT02927366View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

QCC374

0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID

DRUG

Placebo Matching

"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"

Trial Locations (5)

15261

Novartis Investigative Site, Pittsburgh

69120

Novartis Investigative Site, Heidelberg

01307

Novartis Investigative Site, Dresden

03722

Novartis Investigative Site, Seoul

CB23 3RE

Novartis Investigative Site, Cambridge

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY